LeafLine Labs blamed a temporary testing disruption, but worried patients say they have come to rely on medical marijuana for the treatment of severe illnesses and pain.
A distribution glitch at one of Minnesota’s two medical marijuana providers has left some patients with little or no supply left for treatment of conditions such as chronic pain, epileptic seizures and Tourette syndrome.
One patient, Katie Kennedy, said she called LeafLine Labs on Monday because she had no cannabis left for the management of her chronic pain and only a two-day supply left for the management of her son’s Tourette and autism.
She said a LeafLine representative replied that it had none available until Friday, though it later provided a small quantity to get her son through the week.
Jeffrey Friedland is CEO of INTIVA Inc., director of CannRx, a founder of Israel Plant Sciences and is very involved in the Cannabis industry in the United States, Canada and Israel.Read more...
Alex Halperin has reported on Marijuana for The L. A. Times, The Washington Post, The Atlantic and many other publications.
He writes the free and confidential newsletter WeedWeek (WeedWeek.net), and lives in Los Angeles. Read more...
Co-Founder and Vice President Government Relations
Ed Keating is a co-founder of Cannabiz Media and oversees government relations efforts.Read more...